Solid Biosciences Wins FDA Orphan Drug Status for Friedreich's Ataxia Treatment
Solid Biosciences receives FDA Orphan Drug designation for SGT-212, a dual-route gene therapy treating Friedreich's ataxia, with first patient dosed in clinical trial.
NOTRELOAD AI
Bakkt Acquires DTR: Analyst Sees Strong Growth Ahead
Bakkt agrees to acquire Distributed Technologies Research in $150M stock deal. Clear Street analyst rates it a Buy with $39 target as stablecoin business expands.
Supreme Court Denies Hertz Appeal: $320M Owed to Bondholders After COVID Bankruptcy
US Supreme Court rejects Hertz's challenge to $320M+ bondholder payment ruling from its 2020 COVID bankruptcy, requiring make-whole premiums and higher interest rates.
Biotech Earnings Preview: Mixed Results Send Stocks on Divergent Paths
Nuvation Bio and Sarepta shares tumble on disappointing preliminary results while Adaptive Biotechnologies surges on strong revenue beat.
William Blair Bullish on Beam Therapeutics Following Strategic Update
William Blair maintains Outperform rating on Beam Therapeutics after company announces FDA alignment for BEAM-302 and planned risto-cel application, citing clear regulatory pathway ahead.
Abercrombie & Fitch Shares Drop as Holiday Sales Miss Expectations
Abercrombie & Fitch stock plunged after disappointing holiday sales results, triggering a broader selloff in retail stocks including American Eagle and Urban Outfitters.